Your session is about to expire
← Back to Search
Neurostimulator
ITN [TrueTear®] - Extranasal Application for Dry Eye Syndrome
N/A
Waitlist Available
Led By Stephen Pflugfelder, MD
Research Sponsored by Allergan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screening (day -60 to day -30) to application visit (day 0)
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to evaluate goblet cell degranulation following acute use of the Intranasal Tear Neurostimulator in participants with dry eye.
Eligible Conditions
- Dry Eye Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ screening (day -60 to day -30) to application visit (day 0)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening (day -60 to day -30) to application visit (day 0)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Difference in Ratio of Degranulated Goblet Cells.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: ITN [TrueTear®] - Intranasal ApplicationExperimental Treatment1 Intervention
Intranasal application of the ITN. Single application at application visit.
Group II: ITN [TrueTear®] - Extranasal ApplicationExperimental Treatment1 Intervention
Extranasal application of the ITN. Single application at application visit.
Find a Location
Who is running the clinical trial?
AllerganLead Sponsor
781 Previous Clinical Trials
276,640 Total Patients Enrolled
Stephen Pflugfelder, MDPrincipal InvestigatorBaylor College of Medicine, Department of Ophthalmology
1 Previous Clinical Trials
20 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger